Listed

Tempest Therapeutics, Inc.: Form 10-K for the period ended Dec 31, 2018

Filed with the SEC on Apr 1, 2019 and accepted by EDGAR at Mar 29, 2019, 17:36 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2018-12-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Operating income12 months2018-01-01 to 2018-12-31−$26.9mus-gaap:OperatingIncomeLoss
Interest expense12 months2018-01-01 to 2018-12-31$134.0kus-gaap:InterestExpense
Net income12 months2018-01-01 to 2018-12-31−$27.2mus-gaap:NetIncomeLoss
Diluted EPS12 months2018-01-01 to 2018-12-31−$17.58us-gaap:EarningsPerShareBasicAndDiluted
Operating cash flow12 months2018-01-01 to 2018-12-31−$23.6mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure12 months2018-01-01 to 2018-12-31$36.0kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2018-12-31$73.3mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2018-12-31$83.4mus-gaap:AssetsCurrent
Total assetsAt period end2018-12-31$84.1mus-gaap:Assets
Current liabilitiesAt period end2018-12-31$9.8mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2018-12-31$11.0mus-gaap:Liabilities
Long-term debtAt period end2018-12-31$383.0kus-gaap:LongTermDebtNoncurrent
Shareholders' equityAt period end2018-12-31$71.0mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001558370-19-002660. Last ingested by Listed: Nov 15, 2026, 00:20 ET. Listed shows no prices and gives no investment advice.